Related Experiment Videos
Anticonvulsants in central pain.
Nanna B Finnerup1, Hanne Gottrup, Troels S Jensen
1Department of Neurology and Danish Pain Research Centre, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus C, Denmark. finnerup@akhphd.au.dk
Expert Opinion on Pharmacotherapy
|October 22, 2002
Summary
Anticonvulsant drugs effectively manage central neuropathic pain (CP) by reducing neuronal hyperexcitability. Lamotrigine is recommended first-line, followed by gabapentin or carbamazepine, showing efficacy comparable to amitriptyline.
Area of Science:
- Neurology
- Pharmacology
Background:
- Central neuropathic pain (CP) presents a significant clinical challenge.
- Neuronal hyperexcitability in damaged central nervous system (CNS) areas is a key factor in CP development.
Purpose of the Study:
- To review the role of anticonvulsants in treating central neuropathic pain.
- To outline current treatment recommendations for CP using anticonvulsant medications.
Main Methods:
- Review of preclinical and clinical studies on anticonvulsant mechanisms and efficacy.
- Analysis of existing literature regarding randomized controlled trials (RCTs) for CP treatment.
Main Results:
- Anticonvulsants modulate neuronal hyperexcitability via GABAergic, sodium/calcium channel, and excitatory amino acid pathways.
- Both first-generation (e.g., carbamazepine) and second-generation (e.g., lamotrigine, gabapentin) anticonvulsants are utilized for CP.
- Limited RCT data exists, but lamotrigine is suggested as first-line, with gabapentin or carbamazepine/oxcarbazepine as alternatives.
Conclusions:
- Anticonvulsants are a cornerstone in managing central neuropathic pain.
- Lamotrigine, gabapentin, and carbamazepine/oxcarbazepine are effective options, with lamotrigine often preferred.
- Further high-quality RCTs are needed to solidify treatment guidelines for CP.